LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • November 16th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations
This License, Development and Commercialization Agreement (this “Agreement”) is entered into as of this 10th day of October, 2020, (the “Effective Date”) by and between
LOAN, SECURED CONVERTIBLE NOTE PURCHASE, AND SECURITY AGREEMENTLoan, Secured Convertible Note Purchase, and Security Agreement • November 16th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
THIS LOAN, SECURED CONVERTIBLE NOTE PURCHASE, AND SECURITY AGREEMENT (the “Agreement”) is made and entered into as of June 27, 2020 (the “Effective Date”), between Mateon Therapeutics, Inc., a Delaware corporation and each of its subsidiaries, including, but not limited to Oncotelic Inc. and PointR Data Inc. (each, a “Subsidiary,” together the “Subsidiaries, and collectively, the “Company”), on the one hand, and Golden Mountain Partners, LLC, a California Limited Liability Company (“Purchaser”), on the other hand.
